Lukasz Kuryk | Immunology and Microbiology | Research Excellence Award
National Institute of Public Health | Poland
Łukasz Kuryk, PhD, is a preclinical immuno-oncology researcher whose work centers on advancing next-generation oncolytic adenoviruses and innovative immune-based cancer therapies through rigorous translational development. With extensive expertise spanning preclinical drug development—including efficacy, safety, biodistribution, and mechanistic immunology—he has contributed significantly to the evolution of modern virotherapy and cancer immunotherapy platforms. As a Principal Investigator leading national and international research initiatives, he develops and evaluates novel viral and immune-modulating therapeutics with the goal of enhancing antitumor immunity and improving clinical outcomes. His career includes impactful roles at the National Institute of Public Health in Poland, where he has served as Associate Professor and Assistant Professor in the Department of Virology, driving research in immuno-oncology and cancer vaccine development. He has also contributed to pioneering studies at the Warsaw University of Technology within the Immuno-Oncology and Immunotherapy Laboratory, working at the interface of engineering, immunology, and infectious disease research. His international engagement includes work as a visiting researcher at the University of Padova, where he explored the use of EV-like nanoparticles as delivery platforms for oncolytic viruses, opening new avenues for therapeutic innovation. A co-inventor on multiple patents in oncolytic virotherapy and cancer vaccine technologies, he is recognized for fostering highly productive academic–industry collaborations that accelerate the translation of experimental therapeutics toward clinical relevance. He has authored more than fifty peer-reviewed publications that contribute to the expanding understanding of viral immunotherapies and tumor–immune interactions, establishing him as an influential scientist in the field. His career reflects a persistent commitment to advancing the scientific foundations and therapeutic potential of immuno-oncology through multidisciplinary collaboration, innovation, and translational impact.
Featured Publications
Mathlouthi, S., Kuryk, L., Rinner, B., Bellio, G., Casagrande, L., Pesce, C., Fragassi, A., Salmaso, S., Mastrotto, F., & Garofalo, M. (2026). A 3D coculture model of hepatocellular carcinoma: Addressing challenges with glycopolymers re-targeted oncolytic viruses. Journal of Drug Delivery Science and Technology, 107658.
Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Data 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma
Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Figures S1 to S7 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma
Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Methods 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma
Shoushtari, A. N., Olszanski, A. J., Nyakas, M., Hornyak, T. J., Wolchok, J. D., Levitsky, V., Kuryk, Ł., Hansen, T. B., & Jäderberg, M. (2025). Supplementary Table 1 from Pilot study of ONCOS-102 and pembrolizumab: Remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma